Ruo-ting Xu

Dr. Ruo-ting Xu

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2019 in Critical Care
Verified
Journal Article
Open access
PDF file
RXRuo-ting Xu
Ruo-ting Xu
CTChuhong Tan
Chuhong Tan
JZJiajia Zhu
Jiajia Zhu
XZXiuli Zeng
Xiuli Zeng
XGXuxuan Gao
Xuxuan Gao
JYJia Yin
Jia Yin
Background: Despite the essential functions of the intestinal microbiota in human physiology, little has been reported about the microbiome in neurocritically ill patients. This investigation aimed to evaluate the characteristics of the gut microbiome in neurocritically ill patients and its changes after admission. Furthermore, we investigated whether the characteristics of the gut microbiome at admission were a risk factor for death within 180 days. Methods: This prospective observational cohort study included neurocritically ill patients admitted to the neurological intensive care unit of a large university-affiliated academic hospital in Guangzhou. Faecal samples were collected within 72 h after admission (before antibiotic treatment) and serially each week. Healthy volunteers were recruited from a community in Guangzhou. The gut microbiome was monitored via 16S rRNA gene sequence analysis, and the associations with the clinical outcome were evaluated by a Cox proportional hazards model. Results: In total, 98 patients and 84 age- and sex-matched healthy subjects were included in the analysis. Compared with healthy subjects, the neurocritically ill patients exhibited significantly different compositions of intestinal microbiota. During hospitalization, the α-diversity and abundance of Ruminococcaceae and Lachnospiraceae decreased significantly over time in patients followed longitudinally. The abundance of Enterobacteriaceae was positively associated with the modified Rankin Scale at discharge. In the multivariate Cox regression analysis, Christensenellaceae and Erysipelotrichaceae were associated with an increased risk of death. The increases in intestinal Enterobacteriales and Enterobacteriaceae during the first week in the neurological intensive care unit were associated with increases of 92% in the risk of 180-day mortality after adjustments. Conclusions: This analysis of the gut microbiome in 98 neurocritically ill patients indicates that the gut microbiota composition in these patients differs significantly from that in a healthy population and that the magnitude of this dysbiosis increases during hospitalization in a neurological intensive care unit. The gut microbiota characteristics seem to have an impact on patients’ 180-day mortality. Gut microbiota analysis could hopefully predict outcome in the future.

1 January 2019 in Atherosclerosis
Verified
Journal Article
Closed access
YYYi Yan
Yi Yan
FHFei He
Fei He
ZLZhonghao Li
Zhonghao Li
RXRuo-ting Xu
Ruo-ting Xu
TLTing Li
Ting Li
WWWei Wu
Wei Wu

11 November 2025 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
JHJia-Ni Huang
Jia-Ni Huang
WZWei-Hao Zhuang
Wei-Hao Zhuang
YLYi-Si Lin
Yi-Si Lin
JXJia-Xue Xu
Jia-Xue Xu
YZYan-Lei Zhang
Yan-Lei Zhang
RXRuo-ting Xu
Ruo-ting Xu
Ischemic stroke remains a major global health burden. Enterococcus, which is enriched in the gut of stroke patients, produces cytolysin—a pore-forming toxin that disrupts cell membranes. Gut barrier damage may allow such toxins to enter circulation and impair the blood–brain barrier (BBB). In this study, cytolysin-induced BBB disruption via NLRP3 inflammasome activation was investigated with the aim of identifying new therapeutic targets for stroke. Ischemic stroke patients were enrolled within 48 h of onset at the First Affiliated Hospital of Wenzhou Medical University. Rectal swabs were collected for 16 S rRNA sequencing and analyzed via QIIME. To investigate the effects of cytolysin-positive Enterococcus on BBB integrity and NLRP3 activation, a photothrombotic stroke model in C57BL/6J mice and in vitro studies with bEnd.3 cells were performed. Cerebral blood flow, BBB permeability, and intestinal barrier function were assessed using established physiological and molecular assays. NLRP3 pathway activation was evaluated by RNA sequencing, qPCR, Western blotting, and ELISA, and its functional role was further confirmed by administration of the selective NLRP3 inhibitor MCC950. Statistical significance was defined as p < 0.05. In a cohort of 100 stroke patients, rectal swabs were collected for 16 S rRNA sequencing and qPCR analysis, and the results identified elevated Enterococcus and cylA gene levels as potential prognostic biomarkers for 360-day mortality. In a photothrombotic stroke mouse model, cytolysin-positive Enterococcus exacerbated stroke severity by increasing BBB permeability. Mechanistically, cytolysin activated nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated pyroptosis, further compromising BBB integrity. Additionally, cytolysin disrupted the intestinal barrier, increased permeability, and may facilitate its entry into the circulation, potentially contributing to BBB damage. Notably, NLRP3 inhibition with MCC950 mitigated neurological deficits and restored BBB integrity. Cytolysin aggravates ischemic stroke by compromising the BBB via NLRP3 activation and disrupting the intestinal barrier. Targeting cytolysin and NLRP3 holds promise as a therapeutic strategy for neuroprotection during ischemic stroke.

28 June 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
YWYongqiang Wang
Yongqiang Wang
HZHewei Zhang
Hewei Zhang
ZYZusen Ye
Zusen Ye
QYQiang Ye
Qiang Ye
XYXuezhi Yang
Xuezhi Yang
YZYanlei Zhang
Yanlei Zhang
Background. Gliomas are primary malignant brain tumors. Despite recent advances in surgery and clinical neuro-oncology, the prognosis of patients with glioma is still poor. Therefore, there is an urgent need to find new therapeutic drugs. Methods. Here, we have studied the anticancer effect of maslinic acid in glioma and explored its potential molecular mechanism. CCK-8, Ki67 immunofluorescence, and colony formation tests are used to detect the proliferation of glioma cells. Transwell and migration experiments are used to detect the function of cell invasion and migration, and RNA-seq was performed to identify differentially expressed genes. Western blot analysis helps us identify important signaling pathways. Finally, the anticancer effect of maslinic acid was confirmed in vivo through tumor xenografting experiments. Results. Our experiments obtained high-throughput data on the treatment of maslinic acid in glioma. We found that maslinic acid significantly inhibits the proliferation, invasion, and migration of glioma cells and promotes the apoptosis of glioma cells via suppressing MAPK signaling. Conclusions. This is the first time to analyze the mechanism of maslinic acid against glioma based on transcription. Our experiments show that maslinic acid may be a useful natural product for the treatment of glioma.

12 June 2025 in Translational Stroke Research
Verified
Journal Article
Closed access
PDF file
YLYi-Si Lin
Yi-Si Lin
JCJia-Hao Chen
Jia-Hao Chen
WZWei-Hao Zhuang
Wei-Hao Zhuang
JHJia-Ni Huang
Jia-Ni Huang
YCYi-Han Chen
Yi-Han Chen
RXRuo-ting Xu
Ruo-ting Xu

1 March 2016
Verified
Journal Article
Closed access
RXRuo-ting Xu
Ruo-ting Xu
HZHui Zhou
Hui Zhou
WLWei-Lu Liu
Wei-Lu Liu
WWWei Wu
Wei Wu
XLXian-Yan Liu
Xian-Yan Liu
MZMing Zhao
Ming Zhao